title: Adverse interaction between steroid hormones and anticholinesterase drugs.
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000818:Animals; D001001:Anura; D002800:Cholinesterase Inhibitors / Q000037:antagonists & inhibitors* / Q000627:therapeutic use; D003907:Dexamethasone / Q000494:pharmacology; D004347:Drug Interactions; D004491:Edrophonium / Q000494:pharmacology; D004966:Estrogens, Conjugated (USP) / Q000494:pharmacology; D005938:Glucocorticoids / Q000494:pharmacology*; D006854:Hydrocortisone / Q000494:pharmacology / Q000627:therapeutic use; D008274:Magnesium / Q000494:pharmacology; D008297:Male; D008775:Methylprednisolone / Q000494:pharmacology; D009119:Muscle Contraction / Q000187:drug effects; D009132:Muscles / Q000187:drug effects*; D009157:Myasthenia Gravis / Q000188:drug therapy; D009388:Neostigmine / Q000037:antagonists & inhibitors; D011239:Prednisolone / Q000494:pharmacology; D011241:Prednisone / Q000494:pharmacology; D011729:Pyridostigmine Bromide / Q000037:antagonists & inhibitors; D051381:Rats; D012584:Sciatic Nerve / Q000187:drug effects*; D014403:Tubocurarine / Q000494:pharmacology
chemical_list: D002800:Cholinesterase Inhibitors; D004966:Estrogens, Conjugated (USP); D005938:Glucocorticoids; D009388:Neostigmine; D004491:Edrophonium; D003907:Dexamethasone; D011239:Prednisolone; D008274:Magnesium; D011729:Pyridostigmine Bromide; D011241:Prednisone; D014403:Tubocurarine; D006854:Hydrocortisone; D008775:Methylprednisolone